Investment Rating - The report maintains a "Buy" rating for the company, with expected earnings per share (EPS) of 0.50, 0.59, and 0.61 for 2025, 2026, and 2027 respectively, corresponding to price-to-earnings (P/E) ratios of 12x, 10x, and 10x [4]. Core Insights - The company reported a revenue of 88.0 billion yuan for 2024, a decrease of 8.3% year-on-year, while net profit attributable to shareholders was 7.75 billion yuan, an increase of 18.9% year-on-year. For Q1 2025, revenue was 17.6 billion yuan, down 12.1% year-on-year, and net profit was 1.07 billion yuan, down 40.8% year-on-year [2][3]. - The company achieved a significant improvement in thermal power profitability in 2024, with a total electricity generation of 164.7 billion kWh, up 6.6% year-on-year, primarily due to the full operation of the Six Horizontal Power Plant Phase II project and increased electricity demand in Zhejiang Province [2]. - The company plans a cash dividend of 0.29 yuan per share for 2024, representing a 50.2% payout ratio, with a current dividend yield of approximately 5.0% [2][4]. Summary by Sections Financial Performance - In 2024, the company experienced a revenue decline of 8.3% to 88.0 billion yuan, while net profit increased by 18.9% to 7.75 billion yuan. The projected revenues for 2025 and 2026 are 81.78 billion yuan and 83.14 billion yuan, respectively, with expected growth rates of -7.1% and 1.7% [8][10]. - The company’s operating cash flow remains healthy, covering capital expenditures, and reducing the debt-to-asset ratio from 45.7% at the end of 2023 to 42.3% in Q1 2025 [4]. Market Conditions - The decline in electricity prices in Q1 2025 was greater than the reduction in costs, leading to pressure on profitability. The average purchase price for industrial and commercial electricity in Zhejiang Province fell by 72 yuan/MWh year-on-year [3]. - The company’s coal inventory was high at the end of 2024, which has not yet reflected in the financial statements, contributing to the pressure on Q1 2025 earnings [3]. Future Outlook - The company is expected to see marginal improvements in profitability as high-cost inventory is consumed, with anticipated net profits of 6.63 billion yuan, 7.91 billion yuan, and 8.14 billion yuan for 2025, 2026, and 2027, respectively [4][8].

业绩简评 2025 年 4 月 28 日，公司发布 2024 年年度报告，24 年公司实现收 入 26.78 亿元（同比-1.46%），实现归母净利润-1.02 亿元，扣非 归母净利润-0.85 亿元。 同时公司发布 2025 年一季报，25Q1 公司实现营业收入 7.42 亿元 （同比+9.82%），归母净利润 0.27 亿元（同比+61.18%），扣非归母 净利润 0.28 亿元（同比+48.37%）。 经营分析 盈利能力改善显著，成本控制成效初显。25Q1 公司毛利率约为 39.34%，毛利率相对稳健。费用端，25Q1 公司管理费用率为 12.44%(同比下降 2.61pct)，销售费用率为 16.52%，同比基本持 平。整体来看，公司成本管控措施逐步显效，新院对整体利润的拖 累可能有所减轻，未来盈利能力有望逐步改善。 扩张步伐稳健，新院逐步产生贡献。公司坚持"全国连锁化+同城 一体化"战略，聚焦中心城市并进行同城加密布局。随着新院逐渐 成熟，有望为未来增长提供动力，并逐步改善盈利能力。 盈利预测、估值与评级 我们预计 2025-2027 年公司分别实现归母净利润 1.30/1.61/2.02 亿元，同 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Views - The company reported a revenue of 7.34 billion RMB for 2024, representing a year-on-year growth of 8.5%, and a net profit attributable to shareholders of 2.59 billion RMB, up 13.4% year-on-year [2]. - For Q1 2025, the company achieved a revenue of 2.05 billion RMB, down 12.3% year-on-year, with a net profit of 830 million RMB, a decrease of 9.5% year-on-year [2]. - The overall performance for Q4 2024 and Q1 2025 shows a revenue decline of 9% and a net profit decline of 8% compared to the previous year, which was below market expectations [2]. Revenue Analysis - In terms of product revenue, mid-to-high-end and regular liquor generated 5.71 billion RMB and 1.29 billion RMB in 2024, with year-on-year growth of 13.8% and a decline of 6.5% respectively [3]. - For Q1 2025, mid-to-high-end and regular liquor revenues were 1.72 billion RMB and 240 million RMB, reflecting a year-on-year decrease of 8.6% and 32.1% respectively [3]. - The revenue from provincial and out-of-province sales in 2024 was 5.09 billion RMB and 1.91 billion RMB, with year-on-year growth of 12.8% and 1.3% respectively [3]. Profitability and Financial Metrics - The net profit margin for 2024 increased by 1.5 percentage points to 35.3%, with a gross margin increase of 2.9 percentage points [4]. - In Q1 2025, the net profit margin rose by 1.3 percentage points to 40.5%, with a gross margin increase of 1.5 percentage points [4]. - The report forecasts net profits of 2.72 billion RMB, 2.90 billion RMB, and 3.26 billion RMB for 2025, 2026, and 2027 respectively, with corresponding growth rates of 4.9%, 6.6%, and 12.3% [5]. Valuation Metrics - The expected earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 3.40 RMB, 3.62 RMB, and 4.07 RMB respectively [5]. - The current stock price corresponds to price-to-earnings (PE) ratios of 14.4, 13.5, and 12.0 for the years 2025, 2026, and 2027 [5].

2025 年 4 月 28 日，公司披露 24 年年报及 25 年一季报。1）24 年实现营收 14.2 亿元，同比-49.7%；实现归母净利 0.1 亿元， 同比-97.7%。2）25Q1 实现营收 3.4 亿元，同比-30.3%；实现归 母净利 0.3 亿元，同比-56.8%。业绩仍处于承压阶段。 分产品来看，24 年内参/酒鬼/湘泉/其他系列分别实现营收 2.4/8.3/0.8/2.7 亿元，同比-67%/-49%/+8%/-31%，其中销量分 别-56%/-46%/+19%/-20%，吨价分别-25%/-6%/-10%/-13%，吨价 下行致使内参/酒鬼/其他系列毛利率分别-2.4/-2.9/-10.1pct。 期内公司仍着手去化渠道遗留库存问题，聚焦消费者扫码、宴席 活动，期内宴席、消费者扫码有明显增长。公司也阶段性开始梳 理产品架构，酒鬼酒 SKU 压减 50%，构建"2+2+2"战略单品体 系，即 2 个战略单品（内参、红坛）、2 个重点单品（妙品、透明 装）、2 个馥郁香基础单品（内品、湘泉）。 分渠道来看，24 年线上/线下分别实现营收 1.9/12.3 亿元，同比 -34%/-51%。此外 ...

2025 年 4 月 28 日，公司披露 24 年年报及 25 年一季报。1）24 年 实现营收 22.0 亿元，同比-1.3%；归母净利 2.9 亿元，同比-15.9%。 2）25Q1 实现营收 8.0 亿元，同比-4.3%；归母净利 1.4 亿元，同 比-9.3%。业绩表现符合预期，外部环境扰动下仍有承压。 从营收结构来看：1）产品端，24 年高档/中档/低档分别实现营收 15.3/5.1/1.3 亿元，同比+4.3%/-8.2%/-20.5%，其中销量分别- 13.6%/-6.5%/-27.1%，吨价分别+20.7%/-1.8%/+9.0%。25Q1 高档 /中档/低档分别实现营收6.2/1.3/0.3亿元，同比+8.8%/-30.7%/- 41.0%。公司产品结构提升明显，伊力王等自营产品有不错增长。 2）区域端，24 年疆内/疆外分别实现营收 16.0/5.7 亿元，同比- 5.8%/+16.7%；25Q1 疆内/疆外分别实现营收 7.0/0.9 亿元，同比 +3.5%/-37.9%。3）渠道端，24 年直销/线上/批发分别实现营收 4.9/1.3/15.4 亿元，同比+90.9%/-1.7%/-1 ...

业绩简评 2025 年 4 月 28 日公司披露 2024 年年报及 2025 年一季报，2024 年全年公司实现营收 178 亿元，同比增长 19.1%；实现归母净利润 18.1 亿元，同比下降 9.7%，实现扣非归母净利 15.9 亿元，同比 下降 1.8%。2025 年一季度公司实现营收 21.9 亿元，同比增长 26.6%；实现归母净利润-1.91 亿元，同比下降 172%。 经营分析 制造业务盈利筑底，"两海"突破有望带动盈利回升：2024 年公司 风机制造板块实现收入 136 亿元，同比增长 13.8%，实现毛利率 10.99%，同比下降 0.19pct。2024 年以来公司"两海"业务取得多 项重大突破：海外方面，公司深耕中亚、南亚、东南亚等类中国市 场，突破欧洲高端市场，在印度、哈萨克斯坦、菲律宾、德国等地 区实现订单获取，全年新签项目合同近 2GW；海上方面，公司中标 揭阳石碑山 200MW 风电项目及河北建投祥云岛 250MW 海风项目， 海上机型进入批量化交付阶段。2024 年公司海外毛利率约 21.7%， 较国内风机业务毛利率高 10pct 以上，预计随着公司"两海"持续 突破，交付占 ...

业绩简评 2025 年 4 月 28 日，公司发布 2024 年年度报告，24 年公司实现收 入 26.78 亿元（同比-1.46%），实现归母净利润-1.02 亿元，扣非 归母净利润-0.85 亿元。 同时公司发布 2025 年一季报，25Q1 公司实现营业收入 7.42 亿元 （同比+9.82%），归母净利润 0.27 亿元（同比+61.18%），扣非归母 净利润 0.28 亿元（同比+48.37%）。 经营分析 屈光术式迭代有望驱动增长，强刚需项目稳健增长。分业务看，屈 光项目 2024 年收入 12.27 亿元（同比下降 5.31%），毛利率 47.02% （同比下降 4.56pct）。公司持续引进蔡司全飞秒精准 4.0 等新技 术，有望进一步巩固竞争优势。白内障项目收入 5.76 亿元（同比 下降 3.04%），受人工晶体国采全面落地及 DRG/DIP 支付改革影响， 呈现"量增价减"态势。24 年白内障项目毛利率 38.93%（同比下 降 4.44pct）。公司通过引进专家、提升服务效率吸引患者，并推 广高端晶体应对集采影响。此外视光项目收入 3.86 亿元，同比下 降 2.60%；综合眼病项目收 ...

业绩简评 0 500 1,000 1,500 2,000 2,500 3,000 3.00 4.00 5.00 6.00 7.00 240429 240729 241029 250129 人民币(元) 成交金额(百万元) 成交金额 吉电股份 沪深300 | 公司基本情况（人民币） | | | | | | | --- | --- | --- | --- | --- | --- | | 项目 | 2023 | 2024 | 2025E | 2026E | 2027E | | 营业收入(百万元) | 14,443 | 13,740 | 14,289 | 15,464 | 16,217 | | 营业收入增长率 | -3.42% | -4.87% | 4.00% | 8.22% | 4.87% | | 归母净利润(百万元) | 908 | 1,099 | 1,312 | 1,469 | 1,533 | | 归母净利润增长率 | 35.24% | 21.01% | 19.38% | 11.94% | 4.36% | | 摊薄每股收益(元) | 0.326 | 0.303 | 0.362 | 0.405 | 0.423 | ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company, setting a target price of HKD 70.24 per share based on a 7.0x PS valuation for 2025 [4]. Core Viewpoints - The company is positioned as a leading player in the marketing and sales SaaS sector in China, with a diverse product matrix and strong growth potential driven by AI technology and market dynamics [2][3][4]. - The company has demonstrated a robust revenue growth trajectory, with a projected CAGR of 31.1% from 2020 to 2024, and an expected revenue of HKD 23.66 billion in 2025 [4][62]. - The company’s AI+SaaS product offerings are expected to enhance customer payment willingness and drive revenue growth, supported by a growing number of large clients and an expanding sales team [9][40][41]. Summary by Sections Investment Logic - The diversification of traffic sources is leading to a trend towards holistic marketing, increasing the demand for marketing and sales tools. The rationalization of investment in the SaaS sector is clearing out smaller players, providing more space for leading domestic firms [2]. - The company has served over 200,000 enterprises and achieved a revenue of HKD 840 million in 2024, with a market share of approximately 2.4%, making it the industry leader [2][22]. Business Model and AI Strategy - The company’s product matrix and business model closely resemble that of HubSpot, which has achieved significant revenue growth in the U.S. market. The company aims to replicate this success in China [3][50]. - The company has launched several AI-driven products, including the Tforce marketing model and the AI-Agentforce platform, which are expected to enhance its service offerings and market competitiveness [9][35]. Financial Projections and Valuation - Revenue projections for 2025, 2026, and 2027 are HKD 23.66 billion, HKD 30.22 billion, and HKD 37.08 billion, respectively, with year-on-year growth rates of 51.78%, 27.75%, and 22.71% [4][76]. - The adjusted net profit is expected to turn positive in 2024, with projections of HKD 0.70 billion, HKD 1.12 billion, and HKD 2.24 billion for the following years [4][70]. Product and Marketing Dimensions - The company’s AI+SaaS product matrix is continuously expanding, with 311 functional modules by the end of 2024, significantly enhancing customer engagement and revenue per client [9][33]. - The company is actively expanding its client base, particularly among government and large state-owned enterprises, which is expected to contribute significantly to revenue growth [9][40]. Competitive Landscape - The marketing and sales SaaS market in China remains fragmented, but the report anticipates a consolidation towards leading players as competition intensifies [2][23]. - The company is well-positioned to capture a larger market share due to its comprehensive product offerings and strong financial backing for R&D [2][26].

Group 1 - The report highlights the ongoing escalation of the global tariff war, particularly between the US and China, which is expected to lead to increased volatility in equity markets and a potential "hard landing" for the US economy [2][10][11] - Domestic economic indicators show a weakening trend, with March data reflecting a 12.4% year-on-year increase in exports, driven by a low base and export rush, while imports fell by 4.3%, indicating persistent domestic demand issues [12][13] - The report emphasizes the need to shift investment strategies from small-cap growth to large-cap value defensive stocks, anticipating this transition to last at least until signs of an earnings bottom emerge [2][10][13] Group 2 - Growth-oriented dividend assets are defined as those sacrificing some dividend yield for potential profit improvement through capital expenditure, which may lead to higher valuations in the market [3][23] - The report identifies two main drivers for growth-oriented dividend assets: the expectation of fiscal policy support and the potential for rising dividend yields, which can help avoid static valuation traps [3][23][26] - A comprehensive screening model for growth-oriented dividend assets has been developed, focusing on five key factors: relative dividend yield advantage, stable dividend payout ratio, ample operating cash flow, stable or improving ROE, and increasing capital expenditure [3][35][34] Group 3 - The report suggests a differentiated approach to sector allocation, recommending a reduction in exposure to AI sectors with low penetration rates, while increasing allocation to structural technology growth areas and growth-oriented dividend assets [4][23] - Specific sectors highlighted for increased allocation include telecommunications, infrastructure, and consumer sectors, which are expected to benefit from fiscal expansion and capital expenditure [4][23][24] - The report also notes that gold stocks and innovative pharmaceuticals are positioned to benefit from rising gold prices and improving profit margins, respectively [4][23]